FTSE on a downer over US drug fears

clock

Fears about the introduction of price controls on drugs in the US have pushed the FTSE 100 index down this morning, as such a move is likely to have an impact of the profitability of GlaxoSmithKline.

The FTSE 100 index is down 18 points or 0.3% to 6,212.6, dragged down in the main by GlaxoSmithKline, Europe's biggest pharmaceutical firm, which is down 20p, or1.44% to £13.66 and AstraZeneca, its closest rival, which also dropped 78p or 2.5% to £29.97 as the Senate is likely to cut the price of medicare in the US. British Airways has also slipped on an oil price increase, as the price of a barrel of crude jumped 2.2% to $61.16 a barrel in New York yesterday because US officials say diesel availability has dropped. It share value is down 4p or 0.87% to 454p. In contrast, however, mobile ...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Partner Insight: Debt, deficits, and market resilience: Is your portfolio prepared?

Partner Insight: Debt, deficits, and market resilience: Is your portfolio prepared?

The world is awash in debt. In the US, government borrowing has surged past 100% of GDP, and the fiscal deficit is at a level typically seen in wartime. Other major economies are in similar situations. So, what does this deluge of debt mean for markets?

Orbis Investments
clock 15 May 2025 • 5 min read
Three Invesco funds fail to deliver value to investors

Three Invesco funds fail to deliver value to investors

Manager's annual assessment found some poor performance

clock 14 May 2025 • 2 min read
Darius McDermott: Old demographics, new innovations — so why isn't healthcare booming?

Darius McDermott: Old demographics, new innovations — so why isn't healthcare booming?

'The sector should be flying — but it isn't'

Darius McDermott
clock 08 May 2025 • 5 min read